Febuxostat는 무증상 고요산혈증 환자에서 경동맥 죽상경화증의 진행을 지연시키지 않습니다: 무작위 대조 시험

7.0 mg/dL) and maximum IMT of the common carotid artery (CCA) ≥1.1 mm at screening were allocated equally using a central web system to receive either dose-titrated febuxostat (10–60 mg daily) or as a control-arm, non-pharmacological lifestyle modification for hyperuricemia, such as a healthy diet and exercise therapy. Of the 514 enrolled participants, 31 were excluded from the analysis, with the remaining 483 people (mean age 69.1 years [standard deviation 10.4 years], female 19.7%) included in the primary analysis (febuxostat group, 239; control group, 244), based on a modified intention-to-treat principal. The carotid IMT images were recorded by a single sonographer at each site and read in a treatment-blinded manner by a single analyzer at a central core laboratory. The primary endpoint was the percentage change from baseline to 24 months in mean IMT of the CCA, determined by analysis of covariance using the allocation adjustment factors (age, gender, history of type 2 diabetes, baseline SUA, and baseline maximum IMT of the CCA) as the covariates. Key secondary endpoints included changes in other carotid ultrasonographic parameters and SUA and the incidence of clinical events. The mean values (± standard deviation) of CCA-IMT were 0.825 mm ± 0.173 mm in the febuxostat group and 0.832 mm ± 0.175 mm in the control group (mean between-group difference [febuxostat − control], −0.007 mm [95% confidence interval (CI) −0.039 mm to 0.024 mm; P = 0.65]) at baseline; 0.832 mm ± 0.182 mm in the febuxostat group and 0.848 mm ± 0.176 mm in the control group (mean between-group difference, −0.016 mm [95% CI −0.051 mm to 0.019 mm; P = 0.37]) at 24 months. Compared with the control group, febuxostat had no significant effect on the primary endpoint (mean percentage change 1.2% [95% CI −0.6% to 3.0%] in the febuxostat group (n = 207) versus 1.4% [95% CI −0.5% to 3.3%] in the control group (n = 193); mean between-group difference, −0.2% [95% CI −2.3% to 1.9%; P = 0.83]). Febuxostat also had no effect on the other carotid ultrasonographic parameters. The mean baseline values of SUA were comparable between the two groups (febuxostat, 7.76 mg/dL ± 0.98 mg/dL versus control, 7.73 mg/dL ± 1.04 mg/dL; mean between-group difference, 0.03 mg/dL [95% CI −0.15 mg/dL to 0.21 mg/dL; P = 0.75]). The mean value of SUA at 24 months was significantly lower in the febuxostat group than in the control group (febuxostat, 4.66 mg/dL ± 1.27 mg/dL versus control, 7.28 mg/dL ± 1.27 mg/dL; mean between-group difference, −2.62 mg/dL [95% CI −2.86 mg/dL to −2.38 mg/dL; P < 0.001]). Episodes of gout arthritis occurred only in the control group (4 patients [1.6%]). There were three deaths in the febuxostat group and seven in the control group during follow-up. A limitation of the study was the study design, as it was not a placebo-controlled trial, had a relatively small sample size and a short intervention period, and only enrolled Japanese patients with asymptomatic hyperuricemia./p>

7.0 mg/dL and a maximum CCA-IMT ≥1.1 mm measured at eligibility assessment, defined as a carotid arterial plaque (localized protruding lesion) in accordance with the guidelines of the Japan Society of Ultrasonic in Medicine and the Japan Academy of Neurosonology [15]. Key exclusion criteria were the administration of any SUA-lowering agents within the 8-week period prior to assessment of eligibility, the presence of gouty tophus, or symptoms of gout arthritis within one year before assessment of eligibility./p>7.5-MHz linear transducer was performed at each site in a blinded manner by an expert, trained sonographer who had attended a lecture on acquiring images of the carotid IMT. All the imaging data were stored as JPEG files and then sent to the core imaging laboratory, where an expert analyzer measured the IMT values in a blinded manner using an automated IMT measurement software program (Vascular Research Tools 5, Medical Imaging Applications LLC, Coralville, IA) [18]./p>

8.0 mg/dL) tended to have a greater percentage change in mean CCA-IMT, although the difference between the two groups was not statistically significant (strongS2 Fig/strong). Other carotid ultrasonographic values and their changes from baseline also did not differ between the treatment groups at any time point (strongTable 2/strong)./p>